Recombinant Mouse TNFSF7/CD70 Protein (Fc Tag)

Catalog Number: PKSM040343

Note: *Centrifuge before opening to ensure complete recovery of vial contents.*

Description

Species	Mouse
Source	HEK293 Cells-derived Mouse TNFSF7/CD70 protein Gln47-Pro195, with an N-terminal mFc
Calculated MW	43.1 kDa
Accession	NP_035747.1
Bio-activity	Immobilized mouse CD27-His at 10 μg/mL (100 μL/well) can bind mouse CD70, the EC_{50} of mouse CD70 is 10-50 ng/mL.

Properties

Purity	> 95% as determined by reducing SDS-PAGE.
Endotoxin	< 1.0 EU per μg of the protein as determined by the LAL method.
Storage	Generally, lyophilized proteins are stable for up to 12 months when stored at -20 to -80°C. Reconstituted protein solution can be stored at 4-8°C for 2-7 days. Aliquots of reconstituted samples are stable at < -20°C for 3 months.
Shipping	This product is provided as lyophilized powder which is shipped with ice packs.
Formulation	Lyophilized from sterile PBS, pH 7.4 Normally 5% - 8% trehalose, mannitol and 0.01% Tween 80 are added as protectants before lyophilization. Please refer to the specific buffer information in the printed manual.
Reconstitution	Please refer to the printed manual for detailed information.

Data



Measured by its binding ability in a functional ELISA. Immobilized mouse CD27-His (Cat: PKSM040859) at 10 μg/mL (100 μL/well) can bind mouse CD70 (Cat: PKSM040343), the EC_{50} of mouse CD70 is 10-50 ng/mL.

Background

CD70, a member of the tumor necrosis factor superfamily, is restricted to activated T-and B-lymphocytes and mature dendritic cells. Binding of CD70 to its receptor, CD27, is important in priming, effector functions, differentiation and memory formation of T-cells as well as plasma and memory B-cell generation. Tight control of CD70 expression is required to prevent lethal immunodeficiency. By selective transcription, CD70 is largely confined to activated lymphocytes and dendritic cells (DC). As a type II transmembrane receptor, CD70 is normally expressed on a subset of B, T and NK cells, where it plays a costimulatory role in immune cell activation. Immunohistochemical analysis of CD70 expression in multiple carcinoma types. The restricted expression pattern of CD70 in normal tissues and its widespread expression in various malignancies makes it an attractive target for antibody-based therapeutics. Investigations to exploit CD70 as a cancer target have lead to the identification of potential antibody-based clinical candidates.

Toll-free: 1-888-852-8623
Tel: 1-832-243-6086
Fax: 1-832-243-6017
Web: www.elabscience.com
Email: techsupport@elabscience.com